Labeling of recombinant proteins with polypeptide fusion partners, or affinity tagging, is a useful method to facilitate subsequent protein purification and detection. Poly-histidine tags (His-tags) are among the most commonly used affinity tags. We report strikingly variable immunodetection of two His-tagged recombinant human erythropoietins (Epo), wild type Epo (Epo wt ) and Epo containing an R103A mutation (Epo R103A ). Both were engineered to contain a C-terminal six residue His-tag. The cDNA constructs were stably transfected into CHO cells and COS-7 cells. Clones from the CHO cell transfections were selected for further characterization and larger-scale protein expression. Three chromatographic steps were utilized to achieve pharmacologically pure Epo. Conditioned media from the Epo-expressing cell lines and protein-containing samples from each step of purification were analyzed by SDS-PAGE and dot blot, using both monoclonal anti-human Epo antibody (AE7A5) and anti-His antibodies. While the successful incorporation of the His-tag into our constructs was confirmed by Epo binding to Ni 2+ -NTA resin and by μLC/MS/MS amino acid sequencing, the levels of immunodetection of His-tagged protein varied markedly depending on the particular anti His-tag antibody used. Such variability in His-tag immunorecognition can lead to critical adverse effects on several analytical methods.
KeywordsEpo; erythropoietin; His-tag; protein purification; His-tag specific antibodies; immunodetection Recombinant DNA technology enables the production of large quantities of highly purified and well-characterized proteins. Methods that will facilitate subsequent protein analysis and purification are of major interest during the initial design of the recombinant protein. Both detection and purification are greatly simplified by engineering the DNA construct so that the encoded protein is fused to a readily detectable affinant peptide partner, a method designated "affinity tagging". There is often a preference for selection of a short affinity tag that can be fused to the target gene more easily using the polymerase chain reaction (PCR) [1,2]. Examples † Corresponding author: Phone: +1 (617) 632-9980, Fax: +1 (617) 632-0401 Email: asytkows@bidmc.harvard.edu. * Address to which proofs should be mailed: Arthur J. Sytkowski, MD, Beth Israel Deaconess Medical Center, 330, Brookline Ave., W/ BL 548, Boston, MA 02215, USA Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In the present study, we generated two cDNAs encoding C-terminal His-tagged variants of recombinant human erythropoietin (Epo) a...